Get the Stockscreener App
4.46
8.98%
-0.44
After Hours:
4.47
0.010
+0.22%
Arbutus Biopharma Corp stock is traded at $4.46, with a volume of 1.69M.
It is down -8.98% in the last 24 hours and up +31.18% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.90
Open:
$4.89
24h Volume:
1.69M
Relative Volume:
1.70
Market Cap:
$854.98M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-10.14
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+6.19%
1M Performance:
+31.18%
6M Performance:
+39.81%
1Y Performance:
+3.48%
1-Day Range:
$4.45
$4.89
1-Week Range:
$4.015
$5.10
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.46 | 885.65M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Is Arbutus Biopharma Corporation showing signs of accumulationQuarterly Portfolio Report & Expert Approved Momentum Ideas - Newser
Adage Capital Partners GP L.L.C. Cuts Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
What to expect from Arbutus Biopharma Corporation in the next 30 daysQuarterly Trade Summary & Daily Entry Point Alerts - Newser
Arbutus Biopharma (NASDAQ:ABUS) Hits New 1-Year HighStill a Buy? - MarketBeat
Relative strength of Arbutus Biopharma Corporation in sector analysisTrade Entry Report & Long-Term Investment Growth Plans - Newser
Combining price and volume data for Arbutus Biopharma CorporationDollar Strength & Reliable Intraday Trade Alerts - Newser
How institutional ownership impacts Arbutus Biopharma Corporation stockPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Key resistance and support levels for Arbutus Biopharma CorporationJuly 2025 Selloffs & Short-Term High Return Ideas - Newser
Invesco Ltd. Has $487,000 Stock Holdings in Arbutus Biopharma Corporation $ABUS - MarketBeat
Two Seas Capital LP Acquires 725,000 Shares of Arbutus Biopharma Corporation $ABUS - MarketBeat
Chart based analysis of Arbutus Biopharma Corporation trendsWeekly Trend Summary & AI Powered Market Trend Analysis - Newser
Combining machine learning predictions for Arbutus Biopharma CorporationMarket Growth Review & AI Driven Price Forecasts - Newser
Is Arbutus Biopharma Corporation forming a bottoming baseWeekly Profit Report & Long-Term Capital Growth Ideas - Newser
Can swing trading help recover from Arbutus Biopharma Corporation lossesTrade Risk Summary & Technical Buy Zone Confirmations - Newser
Real time social sentiment graph for Arbutus Biopharma CorporationJuly 2025 Volume & AI Optimized Trade Strategies - Newser
Arbutus Biopharma Corporation stock daily chart insightsFed Meeting & Low Drawdown Trading Techniques - Newser
Arbutus Biopharma (NASDAQ:ABUS) Cut to “Hold” at Wall Street Zen - Defense World
exit strategy if you’re trapped in arbutus biopharma corporationIPO Watch & Long-Term Capital Growth Strategies - Newser
Volume spikes in Arbutus Biopharma Corporation stock – what they meanJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - Newser
Can a trend reversal in Arbutus Biopharma Corporation lead to recoveryMarket Movement Recap & Safe Entry Zone Identification - Newser
ADAR1 Capital Management LLC Purchases 324,312 Shares of Arbutus Biopharma Corporation $ABUS - MarketBeat
How is Arbutus Biopharma Corporation managing supply chain issuesQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - خودرو بانک
Arbutus Biopharma Corporation stock outlook for YEARBond Market & Safe Entry Point Alerts - Newser
Using AI based signals to follow Arbutus Biopharma CorporationJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
What MACD and RSI say about Arbutus Biopharma CorporationEarnings Summary Report & Weekly Stock Performance Updates - Newser
Custom watchlist performance reports with Arbutus Biopharma CorporationQuarterly Market Summary & Real-Time Volume Analysis Alerts - Newser
How to read the order book for Arbutus Biopharma CorporationQuarterly Profit Report & AI Driven Price Forecasts - Newser
Can Arbutus Biopharma Corporation benefit from deglobalizationJuly 2025 Analyst Calls & Reliable Intraday Trade Plans - khodrobank.com
Using data models to predict Arbutus Biopharma Corporation stock movementLong Setup & Safe Capital Growth Stock Tips - Newser
Does Arbutus Biopharma Corporation qualify in momentum factor screening2025 Market Overview & Weekly High Return Opportunities - Newser
Multi asset correlation models including Arbutus Biopharma Corporation2025 Analyst Calls & Technical Pattern Alert System - Newser
Using flow based indicators on Arbutus Biopharma CorporationWeekly Market Summary & Reliable Intraday Trade Alerts - Newser
Real time scanner hits for Arbutus Biopharma Corporation explainedWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
Technical signs of recovery in Arbutus Biopharma CorporationQuarterly Investment Review & Real-Time Volume Spike Alerts - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryMarket Volume Summary & Free AI Powered Buy and Sell Recommendations - Newser
Real time pattern detection on Arbutus Biopharma Corporation stockMarket Volume Report & Weekly High Momentum Picks - Newser
Will Arbutus Biopharma Corporation outperform the marketJuly 2025 Intraday Action & Fast Gain Stock Tips - Newser
Should value investors consider Arbutus Biopharma CorporationEarnings Risk Report & Expert Verified Stock Movement Alerts - خودرو بانک
Analyzing recovery setups for Arbutus Biopharma Corporation investorsRate Cut & Free Weekly Watchlist of Top Performers - Newser
Is Arbutus Biopharma Corporation vulnerable to short sellersMarket Movement Recap & Daily Profit Maximizing Tips - خودرو بانک
Published on: 2025-09-03 05:15:59 - Newser
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):